

Mazen Noureddin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8199318/publications.pdf>

Version: 2024-02-01

111
papers

6,151
citations

101384

36
h-index

79541

73
g-index

112
all docs

112
docs citations

112
times ranked

5826
citing authors

#	ARTICLE	IF	CITATIONS
1	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
2	NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. <i>American Journal of Gastroenterology</i> , 2018, 113, 1649-1659.	0.2	401
3	Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). <i>Hepatology</i> , 2015, 61, 1239-1250.	3.6	296
4	GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2018, 155, 1463-1473.e6.	0.6	238
5	Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort. <i>Hepatology</i> , 2016, 64, 1969-1977.	3.6	237
6	Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2017, 152, 1449-1461.e7.	0.6	209
7	Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. <i>Hepatology</i> , 2020, 72, 58-71.	3.6	209
8	Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. <i>Gastroenterology</i> , 2020, 158, 1334-1345.e5.	0.6	203
9	Therapeutic pipeline in nonalcoholic steatohepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 373-392.	8.2	173
10	Saroglitazar, a PPAR α / β Agonist, for Treatment of NAFLD: A Randomized Controlled Double-blind Phase 2 Trial. <i>Hepatology</i> , 2021, 74, 1809-1824.	3.6	163
11	Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. <i>Hepatology</i> , 2021, 73, 625-643.	3.6	156
12	Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 3009-3020.	1.4	115
13	Nonalcoholic fatty liver disease: Update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. <i>Experimental Biology and Medicine</i> , 2015, 240, 809-820.	1.1	98
14	AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. <i>Gastroenterology</i> , 2022, 163, 764-774.e1.	0.6	92
15	Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	91
16	Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 616-629.e26.	2.4	91
17	GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 135-141.	1.9	91
18	An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 619-629.e7.	2.4	90

#	ARTICLE	IF	CITATIONS
19	Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2691-2700.	1.8	86
20	Role of aramchol in steatohepatitis and fibrosis in mice. <i>Hepatology Communications</i> , 2017, 1, 911-927.	2.0	84
21	Pathogenesis of NASH: the Impact of Multiple Pathways. <i>Current Hepatology Reports</i> , 2018, 17, 350-360.	0.4	84
22	Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. <i>Gastroenterology</i> , 2020, 159, 1985-1987.e4.	0.6	83
23	Diet Associations With Nonalcoholic Fatty Liver Disease in an Ethnically Diverse Population: The Multiethnic Cohort. <i>Hepatology</i> , 2020, 71, 1940-1952.	3.6	82
24	Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. <i>Journal of Hepatology</i> , 2022, 77, 607-618.	1.8	79
25	Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer. <i>Gastroenterology</i> , 2018, 155, 557-571.e14.	0.6	68
26	MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. <i>Journal of Hepatology</i> , 2022, 76, 781-787.	1.8	67
27	Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 513-526.	1.9	66
28	Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. <i>American Journal of Gastroenterology</i> , 2021, 116, 254-262.	0.2	65
29	Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 617-625.	1.8	59
30	Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. <i>World Journal of Gastroenterology</i> , 2018, 24, 1269-1277.	1.4	55
31	MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study. <i>Liver International</i> , 2020, 40, 2242-2251.	1.9	48
32	Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1109-1123.	1.9	46
33	Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells. <i>Hepatology</i> , 2017, 65, 1249-1266.	3.6	44
34	The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1531-1541.	3.0	43
35	Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2050-2058.e12.	2.4	41
36	GÎ±12 ablation exacerbates liver steatosis and obesity by suppressing USP22/SIRT1-regulated mitochondrial respiration. <i>Journal of Clinical Investigation</i> , 2018, 128, 5587-5602.	3.9	41

#	ARTICLE	IF	CITATIONS
37	Placebo effect on progression and regression in NASH: Evidence from a meta-analysis. <i>Hepatology</i> , 2022, 75, 1647-1661.	3.6	39
38	Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3366-3394.	1.1	37
39	Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2451-2461.e3.	2.4	37
40	Diet Quality Association with Nonalcoholic Fatty Liver Disease by Cirrhosis Status: The Multiethnic Cohort. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa024.	0.1	34
41	Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12â€‰%620â€‰%736 Individuals. <i>Endocrine Practice</i> , 2022, 28, 667-672.	1.1	34
42	Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality. <i>Hepatology</i> , 2021, 73, 1932-1944.	3.6	33
43	Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017â€‰2018 transient elastography data and application of machine learning. <i>Hepatology Communications</i> , 2022, 6, 1537-1548.	2.0	33
44	Awareness of Nonalcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort. <i>Digestive Diseases and Sciences</i> , 2020, 65, 978-986.	1.1	32
45	Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00105.	1.0	32
46	Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. <i>Hepatology</i> , 2021, 74, 2622-2632.	3.6	31
47	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. <i>Hepatology</i> , 2022, 76, 1121-1134.	3.6	31
48	Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD). <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 379-390.	1.3	30
49	Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 45-54.e6.	2.4	29
50	Promising therapies for treatment of nonalcoholic steatohepatitis. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 343-357.	1.0	28
51	Vitamin D signaling maintains intestinal innate immunity and gut microbiota: potential intervention for metabolic syndrome and NAFLD. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G542-G553.	1.6	27
52	State-level HCC Incidence and Association With Obesity and Physical Activity in the United States. <i>Hepatology</i> , 2021, 74, 1384-1394.	3.6	26
53	Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: The Microbiome, Microbial Markers and Liver Disease Study. <i>Hepatology Research</i> , 2018, 48, 1108-1117.	1.8	26
54	UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1475-1484.	2.4	26

#	ARTICLE	IF	CITATIONS
55	Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study. <i>Genes and Immunity</i> , 2015, 16, 321-329.	2.2	25
56	Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 457-464.	1.3	25
57	The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 797-811.	1.4	24
58	Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)? <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 197-204.	1.9	24
59	Associations Between Reproductive and Hormone-Related Factors and Risk of Nonalcoholic Fatty Liver Disease in a Multiethnic Population. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1258-1266.e1.	2.4	23
60	Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. <i>Hepatology International</i> , 2022, 16, 269-281.	1.9	23
61	Coffee Drinking and Alcoholic and Nonalcoholic Fatty Liver Diseases and Viral Hepatitis in the Multiethnic Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1305-1307.	2.4	22
62	Association of State Medicaid Expansion With Racial/Ethnic Disparities in Liver Transplant Wait-listing in the United States. <i>JAMA Network Open</i> , 2020, 3, e2019869.	2.8	22
63	Association of Genetic Risk Score With NAFLD in An Ethnically Diverse Cohort. <i>Hepatology Communications</i> , 2021, 5, 1689-1703.	2.0	22
64	Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art. <i>Hepatology</i> , 2021, 74, 2233-2240.	3.6	22
65	STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus. <i>Journal of Hepatology</i> , 2020, 73, 9-11.	1.8	21
66	Current and Potential Therapies Targeting Inflammation in NASH. <i>Frontiers in Endocrinology</i> , 2021, 12, 767314.	1.5	20
67	Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. <i>Hepatology</i> , 2022, 76, 1649-1659.	3.6	18
68	Predictors of Mortality in the Critically Ill Cirrhotic Patient: Is the Model for End-Stage Liver Disease Enough?. <i>Journal of the American College of Surgeons</i> , 2017, 224, 276-282.	0.2	17
69	Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis. <i>Liver Cancer</i> , 2021, 10, 407-418.	4.2	17
70	S-adenosylmethionine inhibits the ribonucleoprotein domain family member 1 in murine liver and human liver cancer cells. <i>Hepatology</i> , 2022, 75, 280-296.	3.6	17
71	Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 944-959.	1.9	17
72	Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update. <i>Seminars in Liver Disease</i> , 2022, 42, 379-400.	1.8	17

#	ARTICLE	IF	CITATIONS
73	Free-breathing multitasking multi-echo MRI for whole-liver water-specific T ₁ , proton density fat fraction, and quantification. <i>Magnetic Resonance in Medicine</i> , 2022, 87, 120-137.	1.9	16
74	Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. <i>Gastroenterology</i> , 2020, 159, 422-427.e1.	0.6	15
75	Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. <i>World Journal of Hepatology</i> , 2020, 12, 46-63.	0.8	15
76	A Meta-Analysis and Systematic Review on the Global Prevalence, Risk Factors, and Outcomes of Coronary Artery Disease in Liver Transplantation Recipients. <i>Liver Transplantation</i> , 2022, 28, 689-699.	1.3	15
77	Meta-Analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1076-1087.	1.9	15
78	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.	3.6	15
79	Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights. <i>Hepatology</i> , 2020, 72, 2228-2230.	3.6	14
80	Dietary Protein, Fiber and Coffee Are Associated with Small Intestine Microbiome Composition and Diversity in Patients with Liver Cirrhosis. <i>Nutrients</i> , 2020, 12, 1395.	1.7	14
81	Lifestyle and Hepatocellular Carcinoma What Is the Evidence and Prevention Recommendations. <i>Cancers</i> , 2022, 14, 103.	1.7	14
82	Higher thresholds for the utilization of steatotic allografts in liver transplantation: Analysis from a U.S. national database. <i>PLoS ONE</i> , 2020, 15, e0230995.	1.1	13
83	Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018. <i>Hepatology Communications</i> , 2022, 6, 2253-2261.	2.0	13
84	Impaired 25-hydroxylation of vitamin D in liver injury suppresses intestinal Paneth cell defensins, leading to gut dysbiosis and liver fibrogenesis. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G685-G695.	1.6	12
85	Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 422-424.	3.7	11
86	Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort. <i>World Journal of Hepatology</i> , 2019, 11, 710-718.	0.8	10
87	The impact of COVID-19 on the cascade of care of HCV in the US and China. <i>Annals of Hepatology</i> , 2022, 27, 100685.	0.6	10
88	Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1379-1388.	1.1	9
89	Living in the non-alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients' perspectives. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 570-579.	1.9	9
90	Liver Transplantation for Severe Alcoholic Hepatitis: Report of a Single Center Pilot Program. <i>Transplantation Proceedings</i> , 2018, 50, 3527-3532.	0.3	8

#	ARTICLE	IF	CITATIONS
91	Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinical Therapeutics</i> , 2021, 43, 455-472.	1.1	8
92	Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to Help Humans. <i>Hepatology</i> , 2021, 74, 9-11.	3.6	7
93	Accounting for the Placebo Effect and Optimizing Outcomes in Clinical Trials of Nonalcoholic Steatohepatitis (NASH). <i>Current Hepatology Reports</i> , 2020, 19, 63-69.	0.4	7
94	A Diagnostic Test Meta-Analysis Evaluating Imaging-Based and Blood Biomarker-Based Assessment Tools for Fibrosis After Liver Transplantation. <i>Liver Transplantation</i> , 2022, 28, 659-669.	1.3	6
95	The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease. <i>Clinics in Liver Disease</i> , 2022, 26, 213-227.	1.0	6
96	Estrogen-Driven Growth of Focal Nodular Hyperplasia: Truth or Myth?. <i>ACG Case Reports Journal</i> , 2021, 8, e00531.	0.2	5
97	Increase in Alcoholic Hepatitis as an Etiology for Liver Transplantation in the United States: A 2004-2018 Analysis. <i>Transplantation Direct</i> , 2020, 6, e612.	0.8	5
98	Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge. <i>World Journal of Gastroenterology</i> , 2020, 26, 4018-4035.	1.4	5
99	Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 163-172.	1.9	5
100	Fibrosis Changes in the Placebo Arm of NASH Clinical Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2387.	2.4	3
101	Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3831-3841.	1.1	3
102	Why are there no strategies for NAFLD?. <i>Journal of Hepatology</i> , 2022, 76, 763-764.	1.8	3
103	A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3
104	ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD?. <i>Hepatology</i> , 2022, 76, 295-297.	3.6	2
105	Editorial: role of leucine-metformin-sildenafil combination in the treatment of nonalcoholic fatty liver disease (<sc>NAFLD</sc>). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 378-379.	1.9	1
106	Routine Versus Selective Liver Biopsy During Bariatric Surgery: Postoperative Outcomes and Preoperative Predictors of NASH. <i>Obesity Surgery</i> , 2021, 32, 463.	1.1	1
107	Both Alcoholic and Nonalcoholic Steatohepatitis Is an Emerging Indication for Liver Transplantation in the United States. <i>Digestive Disease Interventions</i> , 2020, 04, 223-234.	0.3	0
108	Sex differences in age at waitlist registration for liver transplantation with nonalcoholic steatohepatitis as primary indication. <i>Clinical Transplantation</i> , 2021, 35, e14163.	0.8	0

#	ARTICLE	IF	CITATIONS
109	A217 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL. Journal of the Canadian Association of Gastroenterology, 2021, 4, 249-250.	0.1	0
110	IDDF2021-ABS-0095â€¦A meta-analysis and systematic review on the global prevalence, risk factors and outcomes of coronary artery disease in liver transplant recipients. , 2021, , .		0
111	Subclinical hepatic fibrosis is associated with coronary microvascular dysfunction by myocardial perfusion reserve index: a retrospective cohort study. International Journal of Cardiovascular Imaging, 2022, , 1.	0.7	0